Evaxion A/S (EVAX) Competitors $3.11 -0.10 (-3.12%) Closing price 03:55 PM EasternExtended Trading$3.11 0.00 (0.00%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVAX vs. AIMD, LEXX, BLRX, ATHA, ADAP, EDSA, IMNN, MTVA, NEUP, and PRPHShould you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Ainos (AIMD), Lexaria Bioscience (LEXX), BioLineRx (BLRX), Athira Pharma (ATHA), Adaptimmune Therapeutics (ADAP), Edesa Biotech (EDSA), Imunon (IMNN), MetaVia (MTVA), Neuphoria Therapeutics (NEUP), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Evaxion A/S vs. Its Competitors Ainos Lexaria Bioscience BioLineRx Athira Pharma Adaptimmune Therapeutics Edesa Biotech Imunon MetaVia Neuphoria Therapeutics ProPhase Labs Evaxion A/S (NASDAQ:EVAX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Which has better valuation & earnings, EVAX or AIMD? Evaxion A/S has higher revenue and earnings than Ainos. Evaxion A/S is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvaxion A/S$3.18M1.37-$10.57M-$1.32-2.36Ainos$20K957.63-$14.86M-$4.99-0.82 Do analysts rate EVAX or AIMD? Evaxion A/S currently has a consensus target price of $10.00, suggesting a potential upside of 221.54%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Evaxion A/S is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is EVAX or AIMD more profitable? Ainos has a net margin of 0.00% compared to Evaxion A/S's net margin of -316.03%. Ainos' return on equity of -108.25% beat Evaxion A/S's return on equity.Company Net Margins Return on Equity Return on Assets Evaxion A/S-316.03% -319.52% -63.56% Ainos N/A -108.25%-56.94% Do institutionals & insiders hold more shares of EVAX or AIMD? 11.0% of Evaxion A/S shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 10.4% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to EVAX or AIMD? In the previous week, Evaxion A/S had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Evaxion A/S and 1 mentions for Ainos. Evaxion A/S's average media sentiment score of 0.67 beat Ainos' score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the media. Company Overall Sentiment Evaxion A/S Positive Ainos Neutral Which has more risk & volatility, EVAX or AIMD? Evaxion A/S has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500. SummaryEvaxion A/S beats Ainos on 10 of the 16 factors compared between the two stocks. Get Evaxion A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVAX vs. The Competition Export to ExcelMetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.36M$2.07B$5.74B$9.77BDividend YieldN/AN/A4.40%4.08%P/E Ratio-2.3637.6230.4126.04Price / Sales1.379.64428.97104.72Price / CashN/A53.5525.7828.79Price / Book-2.6410.869.706.08Net Income-$10.57M-$63.67M$3.27B$265.64M7 Day Performance2.30%4.02%3.94%3.11%1 Month Performance14.34%1.05%3.81%0.39%1 Year Performance-79.81%27.02%31.26%18.52% Evaxion A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVAXEvaxion A/S1.9424 of 5 stars$3.11-3.1%$10.00+221.5%-79.6%$4.36M$3.18M-2.3660AIMDAinos0.6037 of 5 stars$3.35-3.2%N/A+20.0%$16.12M$20K-0.6740LEXXLexaria Bioscience3.3381 of 5 stars$0.84+2.1%$4.00+378.2%-65.3%$16.03M$460K-1.257Gap UpBLRXBioLineRx3.3813 of 5 stars$3.83+3.2%$26.00+578.9%-86.9%$15.81M$28.94M-0.4440ATHAAthira Pharma3.0756 of 5 stars$0.39-1.9%$0.50+27.3%-87.7%$15.80MN/A-0.2540Positive NewsGap DownADAPAdaptimmune Therapeutics2.0539 of 5 stars$0.07+17.6%$1.35+1,831.0%-95.0%$15.77M$65.09M-0.11490High Trading VolumeEDSAEdesa Biotech1.5265 of 5 stars$2.31+3.4%$5.00+116.9%-45.6%$15.73MN/A-1.7520Gap UpHigh Trading VolumeIMNNImunon1.2434 of 5 stars$6.48+1.3%$232.50+3,488.0%-66.4%$15.62M$500K-0.5030MTVAMetaVia2.4808 of 5 stars$0.65+1.7%$7.50+1,052.8%N/A$15.49MN/A0.008NEUPNeuphoria Therapeutics1.1701 of 5 stars$7.79-3.8%$21.00+169.6%N/A$15.23M$10K0.00N/AAnalyst ForecastPRPHProPhase Labs1.2395 of 5 stars$0.33-4.4%N/A-87.5%$14.51M$6.77M-0.27130 Related Companies and Tools Related Companies Ainos Competitors Lexaria Bioscience Competitors BioLineRx Competitors Athira Pharma Competitors Adaptimmune Therapeutics Competitors Edesa Biotech Competitors Imunon Competitors MetaVia Competitors Neuphoria Therapeutics Competitors ProPhase Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVAX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.